IDRSF (Idorsia) Short-Term Debt : $236.07 Mil (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Idorsia Short-Term Debt?

Idorsia's Short-Term Debt for the quarter that ended in Sep. 2024 was $236.07 Mil.

Idorsia's quarterly Short-Term Debt declined from Mar. 2024 ($224.98 Mil) to Jun. 2024 ($223.75 Mil) but then increased from Jun. 2024 ($223.75 Mil) to Sep. 2024 ($236.07 Mil).

Idorsia's annual Short-Term Debt stayed the same from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($231.09 Mil).

Idorsia Short-Term Debt Historical Data

The historical data trend for Idorsia's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Idorsia Short-Term Debt Chart

Idorsia Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

231.09

Idorsia Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Short-Term Debt	Get a 7-Day Free Trial															222.07	231.09	224.98	223.75	236.07

Idorsia Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Idorsia Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Idorsia's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Idorsia Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Idorsia Ltd (OTCPK:IDRSF) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

IDIAz:UK 0RQE:UK IDIA:Switzerland

Address

Hegenheimermattweg 91, Allschwil, CHE, 4123

Website

https://www.idorsia.com

Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide innovative therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.